Merck Scores As Judge Spurns New Fosamax Class

Law360, New York (January 4, 2008, 12:00 AM EST) -- Despite months of plaintiffs' lobbying, the federal judge overseeing the Fosamax product liability litigation against pharmaceutical giant Merck & Co. has declined to grant class status to patients who have not yet developed a painful jaw condition allegedly linked to the osteoporosis medication.

On Thursday, Judge John Keenan of the U.S. District Court for the Southern District of New York batted down a motion by patients in Florida, Pennsylvania and Louisiana, maintaining that a class action would not be the proper way to pursue its bid...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.